Jenny Davies

Jenny works with a range of pharmaceutical, biotech and medical device companies. Her unique practice includes negotiating complex, cross-border licensing and collaboration deals, advising on alliance management, and protecting and maintaining her clients’ markets through strategic patent advice and enforcement.

Jenny’s licensing practice focuses on drafting and negotiating license and collaboration agreements for clients, including advising on highly complex, company-transforming transactions, co-promotion and co-development agreements, early-stage research and development agreements, and manufacturing and services agreements.

In her patent practice, she leads UK patent litigation, advises on European Patent Office (EPO) oppositions, and provides extensive guidance on patent analysis and enforcement/defensive strategy. Jenny has coordinated litigation and intellectual property (IP) enforcement in more than 20 countries.

With her biochemistry background and 15 years of experience in the life sciences sector, Jenny understands both the commercial pressures and nuanced technical issues her clients face. She has a special interest in RNA technology stemming from her work during and after the COVID-19 pandemic, where she counselled clients on a broad range of issues from complex collaborations and alliance management to patentability, patent strategy and patent enforcement. Jenny also has considerable experience working with biologics, small molecules and cell therapy.

She is a member of the BioIndustry Association’s IP advisory committee and its supplementary protection certificate (SPC) and exclusivities subcommittee, as well as a regular speaker on patent matters and strategy.

Before joining Cooley, Jenny was the head of the life sciences practice at an international law firm and had a role as acting chief representative officer in Guangzhou, China.